Cover Image
市場調查報告書

地中海型貧血的全球市場

Global Thalassemia Market Report: 2016 Edition

出版商 Koncept Analytics 商品編碼 358800
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
地中海型貧血的全球市場 Global Thalassemia Market Report: 2016 Edition
出版日期: 2016年05月26日 內容資訊: 英文 45 Pages
簡介

本報告提供地中海型貧血的治療方法的市場相關分析,疾病概要和治療方法,全球市場規模 (發病數量、治療費等),各地區的詳細趨勢,主要的推動及阻礙市場要素,企業間競爭現況,主要企業簡介等調查評估。

第1章 概要

  • 簡介
  • 地中海型貧血的種類
    • α地中海型貧血
    • β地中海型貧血
    • 鐮狀β地中海型貧血
  • 症狀和前兆
  • 治療選擇
    • 輸血
    • 骨髓移植

第2章 全球地中海型貧血市場

  • 全球地中海型貧血發病數量:重症度別
  • 全球地中海型貧血診斷數量:各類別
  • 全球輸血依賴性β地中海型貧血發病數量:各地區
  • 全球地中海型貧血市場:各治療法
    • 骨髓移植市場收益額
    • LentiGlobin BB305收益額
    • Luspatercept的收益額

第3章 各地區分析

  • 美國的地中海型貧血市場
    • 美國國內的β地中海型貧血攜帶者/患者人口
    • 美國國內的β地中海型貧血的重病患者人口
    • 美國國內的輸血依賴性β地中海型貧血的患者
    • 美國的親屬間的β地中海型貧血幹細胞移植
  • 歐洲的地中海型貧血市場
    • 歐洲的輸血依賴性β地中海型貧血患者數
    • 歐洲的輸血依賴性β地中海型貧血的重病/輕傷患者

第4章 市場動態

  • 成長推動因素
    • 醫療費用支出的擴大
    • 對幹細胞療法的研究開發 (R&D) 支出額的增額
    • 在東亞、太平洋各國的人口增加
  • 主要趨勢和動靜
    • 地中海型貧血治療的基因治療
    • 鐵螯合劑療法的進步
    • 胎兒血紅素的誘導物質
  • 課題
    • 亞太地區的未滿足需求
    • 高額的治療費
    • 替代性治療方法的缺乏

第5章 競爭環境

  • 骨髓移植療市場上競爭狀態
    • 全球主要企業的收益額比較
    • 全球主要企業的報酬率比較
    • 全球主要企業的市值比較
    • 美國的主要企業的收益額比較
  • 新的治療方法的競爭狀態
    • 新企業的產品平台比較

第6章 企業簡介

  • Lonza Group Ltd
    • 產業概要
    • 財務狀況
    • 產業策略
  • Bluebird Bio
  • Acceleron Pharma, Inc
  • Sangamo Biosciences

圖表一覽

目錄

Thalassemia is a hereditary blood disorder in which a person's body makes an abnormal form of hemoglobin, which is the protein molecule in red blood cells (RBCs), which carries oxygen. The disorder results in unwarranted damage of red blood cells, which leads to anemia. Anemia is a condition in which the body doesn't have adequate amount of normal and healthy red blood cells. There are majorly two types of thalassemia based on these proteins known as the Alpha thalassemia and the Beta thalassemia. There is also a third type viz. Sickle beta thalassemia, which is like a combination of sickle cell disease and beta thalassemia.

Even though it is a rare genetic disorder, the number of people affected by it has been growing with time. While those with thalassemia minor have hardly any threat to their life and only require occasional blood transfusion to sustain, thalassemia major patients need to go for periodic transfusions for a sustained life. In case of infants, thalassemia major often leads to still birth or cause death shortly after the baby's birth. Presently the only cure for thalassemia is a bone marrow transplantation therapy, which is done mostly for severe cases of thalassemia.

The key factors which are anticipated to drive this market include rising healthcare expenditure, rising spending on stem cell therapy research and development and rising population in the East-Asia and Pacific region of the world. Some of the noteworthy developments of this industry include the advances in the iron chelation therapy, development of gene therapy and fetal hemoglobin inducers as potential curatives for thalassemia. However, the growth of respective industry is challenged by the high cost of treatments, lack of alternative treatments and unmet market of the Asia-Pacific.

The report provides a comprehensive study of global thalassemia market and also major regional markets. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. The global thalassemia industry is highly competitive consisting of several companies including the Lonza group, Acceleron Pharma, BlueBird Bio and Sangamo Biosciences etc. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail.

Table of Contents

1. Overview

  • 1.1. Introduction
  • 1.2. Types of Thalassemia
    • 1.2.1. Alpha Thalassemia
    • 1.2.2. Beta Thalassemia
    • 1.2.3. Sickle Beta Thalassemia
  • 1.3. Signs and Symptoms
  • 1.4. Treatment Options
    • 1.4.1. Blood Transfusion
    • 1.4.2. Bone Marrow Transplant

2. Global Thalassemia Market

  • 2.1. Global Thalassemia Incidence by Severity
  • 2.2. Global Thalassemia Diagnosis by Category
  • 2.3. Global Transfusion-Dependent β Thalassemia by Region
  • 2.4. Global Thalassemia Market by Therapy
    • 2.4.1. Global Bone Marrow Transplant Revenue
    • 2.4.2. Global LentiGlobin BB305 Revenue
    • 2.4.3. Global Luspatercept Revenue

3. Regional Analysis

  • 3.1. The US Thalassemia Market
    • 3.1.1. The US β Thalassemia Carrier Patient Population
    • 3.1.2. The US β Thalassemia Major Patient Population
    • 3.1.3. The US Transfusion-Dependent β Thalassemia Patients
    • 3.1.4. The US β Thalassemia Sibling-Matched Stem Cell Transplant
  • 3.2. Europe Thalassemia Market
    • 3.2.1. Europe Transfusion-Dependent β Thalassemia Patients
    • 3.2.2. Europe Transfusion-Dependent β-Thalassemia Major/Intermediate Patients

4. Market Dynamics

  • 4.1. Growth Drivers
    • 4.1.1. Rising Healthcare Expenditure
    • 4.1.2. Rising R&D Spending on Stem Cell Therapy
    • 4.1.3. Rising Population in the East Asia and Pacific Region
  • 4.2. Key Trends and Developments
    • 4.2.1. Gene Therapy for Curing Thalassemia
    • 4.2.2. Advances in Iron Chelation Therapy
    • 4.2.3. Fetal Hemoglobin Inducers
  • 4.3. Challenges
    • 4.3.1. Unmet Market of the Asia-Pacific
    • 4.3.2. High Cost of Therapies
    • 4.3.2. Lack of Alternative Treatments

5. Competitive Landscape

  • 5.1. Competition in Bone Marrow Therapy
    • 5.1.1. Revenue Comparison of the Global Key Players
    • 5.1.2. Profit Margin Comparison of the Global Key Players
    • 5.1.3. Market Cap Comparison of the Global Key Players
    • 5.1.4. Revenue Comparison of Key Players of the US
  • 5.2. Competition in Emerging Therapeutics
    • 5.2.1. Product Pipeline Comparison of Emerging Players

6. Company Profiles

  • 6.1. Lonza Group Ltd
    • 6.1.1. Business Overview
    • 6.1.2. Financial Overview
    • 6.1.3. Business Strategies
  • 6.2. Bluebird Bio
    • 6.2.1. Business Overview
    • 6.2.2. Financial Overview
    • 6.2.3. Business Strategies
  • 6.3. Acceleron Pharma, Inc
    • 6.3.1. Business Overview
    • 6.3.2. Financial Overview
    • 6.3.3. Business Strategies
  • 6.4. Sangamo Biosciences
    • 6.4.1. Business Overview
    • 6.4.2. Financial Overview
    • 6.4.3. Business Strategies

List of Charts

  • Global Thalassemia Incidence by Severity (2015E)
  • Global Thalassemia Diagnosis by Category (2015E)
  • Global Transfusion-Dependent β Thalassemia by Region (2015E)
  • Global Bone Marrow Transplant Revenue (2015E-2020F)
  • Global LentiGlobin BB305 Revenue (2018F-2025F)
  • Global Luspatercept Revenue (2018F-2022F)
  • The US β Thalassemia Carrier Patients - Actual (2014-2015E)
  • The US β Thalassemia Carrier Patients - Forecast (2016F-2020F)
  • The US β Thalassemia Major Patients - Actual (2014-2015E)
  • The US β Thalassemia Major Patients - Forecast (2016F-2020F)
  • The US Transfusion-Dependent β Thalassemia Patients - Actual (2014-2015E)
  • The US Transfusion-Dependent β Thalassemia Patients - Forecast (2016F-2020F)
  • The US β Thalassemia Sibling-Matched Stem Cell Transplant - Actual (2014-2015E)
  • The US β Thalassemia Sibling-Matched Stem Cell Transplant - Forecast (2016F-2020F)
  • Europe Transfusion-Dependent β Thalassemia Patients (2015E-2020F)
  • Europe Transfusion-Dependent β-Thalassemia Major/Intermediate Patients (2015E-2020F)
  • Global Healthcare Expenditure (2010-2015E)
  • Spending on Stem Cell Research in the US (2013-2016F)
  • Population in East-Asia and Pacific (2010-2015E)
  • Revenue Comparison of the Global Key Players (2015)
  • Gross Profit Margin of the Global Key Players (2015)
  • Market Capitalization of the Global Key Players (2015)
  • Revenue Comparison of Key Players of the US (2015)
  • Revenue Share by Business Segments, Lonza Group (2015)
  • Revenue and Net Income, Lonza Group (2011-2015)
  • Revenue and Net Income, Bluebird Bio (2011-2015)
  • Revenue and Net Income, Acceleron Pharma (2011-2015)
  • Revenue and Net Income, Sangamo Biosciences (2011-2015)

List of Tables

  • Product Pipeline of Emerging Players (2015)
  • Product Pipeline, Bluebird Bio (2015)
  • Product Pipeline, Acceleron Pharma (2015)
  • Product Pipeline, Sangamo Biosciences (2015)
Back to Top